ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical-stage company specializing in overcoming cancer treatment resistance, recently unveiled preclinical data on its drug candidate ORIC-114 at the EORTC-NCI-AACR Symposium. The findings underscore ORIC-114's potential as a therapeutic option for non-small cell lung cancer (NSCLC) patients with certain mutations.
Lori Friedman, Ph.D., the company's chief scientific officer, highlighted that ORIC-114 exhibited superior potency and selectivity over other EGFR inhibitors in preclinical studies. Notably, the drug achieved tumor regression across all tested EGFR mutant models, including complete responses in a complex atypical mutant EGFR model.
Comparative analyses further revealed that ORIC-114 maintained high potency across various EGFR mutational classes, with a selectivity profile akin to other inhibitors in cell-based assays. Importantly, the drug showed no off-target kinase liabilities, indicating a promising safety profile.
In a Phase 1 dose escalation study, ORIC-114 also demonstrated complete molecular responses in circulating tumor DNA from patients with EGFR exon 20 insertion and PACC mutations, supporting its broad therapeutic window.
Currently, ORIC-114 is being assessed in a global clinical trial targeting NSCLC patients with EGFR exon 20, HER2 exon 20, and atypical EGFR mutations. Updated results from this trial are expected in the first half of 2025.
ORIC-114 is an irreversible inhibitor designed to target EGFR exon 20, HER2 exon 20, and atypical EGFR mutations. Its ability to penetrate the brain and oral bioavailability positions it as a promising candidate for addressing both systemic and central nervous system (CNS) antitumor activity needs.
